

Recruiting Cats with Large Cell Lymphoma!

We are evaluating the safety of a novel targeted drug Pevonedistat in cats with large cell lymphoma

- Pevonedistat is a potent and selective injectable targeted therapy (NAE inhibitor) that has been studied in human lymphoma patients with minimal toxicities.
- Pevonedistat induces cancer cell death and tumor regression in canine lymphoma pre-clinical studies and made it a promising drug in treating feline large cell lymphoma, which is an aggressive disease without durable treatment response.

Aims:

- Primary aim: Determine **the maximum tolerated dose, tolerability, and adverse event profile of Pevonedistat** in cats diagnosed with large cell lymphoma
- Secondary aim: evaluate the pharmacokinetic profile of the drug and anti-tumor efficacy

Inclusion criteria:

- Cats diagnosed with large cell lymphoma via cytology or histopathology
- No chemotherapy or radiation therapy received within 2 weeks of enrollment
- No other major illness or blood work abnormalities that are expected to limit survival.

Methods:

- Cats will receive 3 subcutaneous injections of Pevonedistat (on Monday, Wednesday and Friday) in each 21-day cycle.
- Recheck appointments are required at the start of each treatment cycle and 1 week after injections (on day 12) including physical exam and blood exams. Urinalysis is required every 21 days (See details in table).
- Imaging exam (abdominal ultrasound or others depending on tumor location) are required on day 0 as baseline and day 42 to evaluate treatment response.
- study will pay for the cost of pevonedistat.
- Owners to cover costs of enrollment tests to confirm qualification and all the study diagnostic tests (with research discount) and recheck exam.

Contacts:

- UW Veterinary Care Oncology Clinical Trial team: Dr. Sean Okada and Dr. Kimberley Law (oncclinicaltrials@vetmed.wisc.edu)
- Phone: 608-263-7600 and leave message for oncology clinical trial team
- Dr. Han-Yun Cheng, Medical Oncology Resident (hcheng97@wisc.edu)
- Dr. Xuan Pan, Medical Oncology Faculty



Study Protocol

- Treatments: scheduled on Mondays, Wednesdays, and Fridays.

Day	0	1	2	3	5	12	21	23	25	32	42	45	47	54	63	65	67	74
Owner consent	x																	
PE, vital signs	x	x	x	x	x	x	x			x	x			x	x			x
Tumor measurement (if applicable)	x	x					x				x				x			
CBC	x					x	x			x	x			x	x			x
Chemistry profile	x						x				x				x			
Urinalysis	x						x				x				x			
Abdominal ultrasound (or other imaging that's available to evaluate response to treatment)	x										x							
Pevonedistat administration		x		x	x		x	x	x		x	x	x		x	x	x	
Blood sample collections for PK study		x		x	x	x	x			x	x			x	x			x